Market Eyes LiveAbbott Laboratories (ABT) Stock Rating & Analysis
MELANY's data-driven read on Abbott Laboratories · Pharmaceutical Preparations.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Its products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, adult nutritional liquids, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment, and it derives roughly 60% of sales outside the United States.
Why ABT scores 57/100
MELANY scores Abbott Laboratories 57/100 by weighing eight factors. Here is how ABT breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 18.8x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 57%
Direction and relative strength of the recent share-price trend.
- Price +14.8% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for ABT
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Abbott Laboratories sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds ABT's momentum and catalyst factors above.
Tracking ABT
Abbott Laboratories rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add ABT to your watchlist and get alerted the moment the rating changes.
How MELANY rates ABT
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Abbott Laboratories's 57/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ABT
Is Abbott Laboratories (ABT) a buy?
As of 2026-08-20, MELANY rated Abbott Laboratories Hold with a composite score of 57/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Abbott Laboratories's MELANY score?
Abbott Laboratories (ABT) has a MELANY composite score of 57/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the ABT stock rating calculated?
MELANY scores ABT from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Abbott Laboratories stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Abbott Laboratories (ABT) Hold with a composite of 57/100 as of 2026-08-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ABT stock price forecast?
MELANY does not publish price targets or forecasts for ABT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 57/100 across eight factors for Abbott Laboratories, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ABT stock overvalued or undervalued?
MELANY's valuation factor currently reads 50/100 for Abbott Laboratories, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ABT's read.
What price should I buy ABT at?
MELANY is not flagging a fresh entry for ABT at its current Hold rating, so there is no entry zone to publish right now. Watchlisting ABT in the free app gets you alerted the moment that changes.
What are the risks of buying ABT stock?
The top risks MELANY currently flags for Abbott Laboratories: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Abbott Laboratories a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 59/100 for Abbott Laboratories, and earnings track record, at 51/100. The 57/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ABT stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 56/100 for ABT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ABT rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-20. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ABT continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
ABT's live rating and alerts are free either way. The app is our flagship.